Physician profile
Christina Snider
NPI 1164402871
$367.31
in general payments reported to CMS, 2019-2025
11 companies · $15.91 in 2025
The $15.91 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.87 · 2022: $25.98 · 2023: $13.98 · 2024: $286 · 2025: $15.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $315.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $104.88 | 2024 | Rexulti, Abilify Asimtufii, Abilify Mycite |
| Tempus Ai, INC | $44.00 | 2024 | |
| Lilly USA, LLC | $41.60 | 2022-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $36.86 | 2024 | Spravato |
| Dexcom, INC. | $25.87 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.74 | 2024 | Trintellix |
| Neurocrine Biosciences, INC. | $23.54 | 2024 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $23.49 | 2024 | |
| Abbvie INC. | $15.32 | 2024 | |
| Novo Nordisk INC | $14.27 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.74 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Snider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.